La Jolla Pharma (LJPC) Price Target Raised at Wedbush Following Positive GCS-100 Trial
Tweet Send to a Friend
Wedbush reiterated an Outperform rating on La Jolla Pharma (NASDAQ: LJPC) and raised its price target to $32.00 (from $27.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
